Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

11 August 2021: Clinical Research

Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center

Jianquan Zhu 1ABCDEF , Yu Zhang 1BC , Meng Wang 1BC , Zhenfa Zhang 1BC , Dongsheng Yue 1BC , Shichang Liu 2BC , Yi Pan 3BC , Changli Wang 1AE*

DOI: 10.12659/MSM.930738

Med Sci Monit 2021; 27:e930738

Table 2 Tumor response before surgery in patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.

Response, n (%)ITT (n=36)Surgery (n=23)
PR23 (63.9)18 (50.0)14 (60.9)18 (78.3)
SD7 (19.4)14 (38.9)9 (39.1)5 (21.7)
PD4 (11.1)2 (5.6)00
NE2 (5.6)2 (5.6)00
ORR23 (63.9)18 (50.0)14 (60.9)18 (78.3)
IRC – Independent Reviewer Committee; ITT – intention-to-treat; NE – not evaluated; ORR – objective response rate; PD – progressive disease; PR – partial response; SD – stable disease.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750